Mr. Shkreli, who gained notoriety for inflating the price of a lifesaving anti-infection drug by 5,000 percent overnight, is accusing the directors and ex-general counsel of using fraud to oust him as top executive in 2014.
The lawsuit, filed in Manhattan federal court, is seeking more than $30 million in damages.
The lawsuit names Gary Lyons, Retrophin’s chairman of the board of directors; Stephen Aselage, the former company CEO and current director; and the firm’s former top lawyer, Margaret Valeur-Jensen.
“After starting a biopharmaceutical company from scratch and turning it into a successful enterprise worth hundreds of millions of dollars, Mr. Shkreli was unceremoniously and illegally ousted from the company at the hands of defendants,” the suit reads, according to CNBC.
Read the full report here.
More articles on pharmacy:
Viewpoint: The $2.1M drug price record won’t last long
J&J to cut 61 jobs in New Jersey
Mallinckrodt to spin off generics unit
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
